Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Incontinence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Erectile Dysfunction 1Carcinoma 1Adenocarcinoma 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 224pembrolizumab 214Carboplatin 173Biopsy 166Cisplatin 159Nivolumab 149Cyclophosphamide 133Radiotherapy 117Paclitaxel 117Gemcitabine 112Bevacizumab 92durvalumab 86Dexamethasone 80Rituximab 76Oxaliplatin 73atezolizumab 68Capecitabine 67venetoclax 66Fluorouracil 66Doxorubicin 65Docetaxel 65Etoposide 63Radiosurgery 60Radiation 57Prednisone 57Cytarabine 56Ipilimumab 55Pemetrexed 54Taxes 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Tadalafil × 90 days × Clear all
NCT07576335 2026-05-08

ROBOPREP

Surgical Outcomes Research Centre (SOuRCe)

Phase 2 Not yet recruiting
64 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Urinary Incontinence

NCT05014776 2026-04-28

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
17 enrolled 8 charts
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡